Track Eton Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Eton Pharmaceuticals, Inc. ETON · Stock Open Eton Pharmaceuticals, Inc. in new tab

63.85 USD
P/E
41.79
EPS
1.54
P/B
21.34
ROE
90.62
Beta
0.83
Target Price
78.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 18, 2027
P/E41.79
EPS1.54
Book Value3.02
Price to Book21.34
Debt/Equity28.00
% Insiders4.846%
Growth
Revenue Growth1.58%
Estimates
Forward P/E19.47
Forward EPS3.31
Target Mean Price78.00

DCF valuation

Model fair value for Eton Pharmaceuticals, Inc. (ETON)
Result
Sign in to run the valuation for ETON.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 78.00 USD (low 70.00, high 82.00) · as of 10 Nov 2026
Low 70.00
Mean 78.00
High 82.00
Price 63.85
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Eton Pharmaceuticals, Inc. Logo Eton Pharmaceuticals, Inc. Analysis (ETON)

United States Health Care Official Website Stock

Is Eton Pharmaceuticals, Inc. a good investment? Eton Pharmaceuticals, Inc. (ETON) is currently trading at 63.85 USD. Market analysts have a consensus price target of 78.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 41.79. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Eton Pharmaceuticals, Inc. is expected to release its next earnings report on March 18, 2027. The market consensus estimate for Forward EPS is 3.31.

Investor FAQ

Does Eton Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Eton Pharmaceuticals, Inc.?

Eton Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 18, 2027. The company currently has a trailing EPS of 1.54.

Company Profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Exchange Ticker
NMS (United States) ETON
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion